The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Ibrutinib plus obinutuzumab/venetoclax in R/R MCL: OAsIs results
Drug resistance in mantle cell lymphoma (MCL) is highly dependent on BCR signaling and the microenvironment. Here, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the OAsIs Phase I trial (NCT02558816), which was designed to assess the safety, tolerability and efficacy of ibrutinib/obinutuzumab, and ibrutinib plus obinutuzumab/venetoclax, with hopes to tackle this resistance in relapsed/refractory MCL. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Rule reveals that as well as having no dose-limiting toxicities, treatment was well tolerated and provided a high level of disease control.
